NVAX
Novavax Inc
NASDAQ: NVAX · HEALTHCARE · BIOTECHNOLOGY
$7.93
-0.56% today
Updated 2026-04-30
Market cap
$1.31B
P/E ratio
3.09
P/S ratio
1.17x
EPS (TTM)
$2.58
Dividend yield
—
52W range
$6 – $12
Volume
4.2M
Novavax Inc (NVAX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
39.20%
Operating margin
14.20%
ROE
-898.00%
ROA
25.70%
Debt/equity
-1.60x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $4.68M | $-23.07M | -38.22% | -525.45% | -492.59% |
| 2007 | $1.51M | $-34.77M | 85.39% | -2,000.73% | -2,297.75% |
| 2008 | $1.06M | $-36.05M | 100.00% | -3,229.32% | -3,388.06% |
| 2009 | $325000.00 | $-38.37M | 100.00% | -11,502.46% | -11,807.38% |
| 2010 | $343000.00 | $-35.71M | 100.00% | -11,222.74% | -10,410.50% |
| 2011 | $14.69M | $-19.36M | 52.32% | -146.92% | -131.84% |
| 2012 | $22.08M | $-28.51M | 33.45% | -134.38% | -129.13% |
| 2013 | $20.91M | $-51.98M | 60.69% | -250.70% | -248.54% |
| 2014 | $30.66M | $-82.95M | 51.12% | -272.97% | -270.55% |
| 2015 | $36.25M | $-156.94M | -348.67% | -433.75% | -432.93% |
| 2016 | $15.35M | $-279.97M | -1,449.79% | -1,752.84% | -1,823.53% |
| 2017 | $31.18M | $-183.77M | 100.00% | -550.78% | -589.46% |
| 2018 | $34.29M | $-184.75M | 100.00% | -507.23% | -538.81% |
| 2019 | $18.66M | $-130.10M | -510.02% | -646.13% | -697.15% |
| 2020 | $475.60M | $-427.50M | 100.00% | -87.62% | -89.89% |
| 2021 | $1.15B | $-1.74B | 100.00% | -147.13% | -152.12% |
| 2022 | $1.60B | $-657.94M | 43.55% | -40.32% | -41.15% |
| 2023 | $556.38M | $-545.06M | 38.21% | -101.82% | -97.97% |
| 2024 | $682.16M | $-187.50M | 70.28% | -36.49% | -27.49% |
| 2025 | $1.12B | $440.30M | 93.67% | 50.14% | 39.19% |